<div>Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).</div>